Acid ceramidase is upregulated in AML and represents a novel therapeutic target

Su Fern Tan, Xin Liu, Todd E. Fox, Brian M. Barth, Arati Sharma, Stephen D. Turner, Andy Awwad, Alden Dewey, Kenichiro Doi, Barbara Spitzer, Mithun Vinod Shah, Samy A.F. Morad, Dhimant Desai, Shantu Amin, Junjia Zhu, Jiangang (Jason) Liao, Jong Yun, Mark Kester, David Claxton, Hong-Gang Wang & 5 others Myles C. Cabot, Edward H. Schuchman, Ross L. Levine, David J. Feith, Thomas P. Loughran

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML.

Original languageEnglish (US)
Pages (from-to)83208-83222
Number of pages15
JournalOncotarget
Volume7
Issue number50
DOIs
StatePublished - Jan 1 2016

Fingerprint

Acid Ceramidase
Acute Myeloid Leukemia
Ceramides
Sphingolipids
Myeloid Cells
Therapeutics
Sphingosine
Survival
Enzyme Assays
Gene Expression Profiling
Inbred C57BL Mouse
Cell Survival
Apoptosis
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Tan, S. F., Liu, X., Fox, T. E., Barth, B. M., Sharma, A., Turner, S. D., ... Loughran, T. P. (2016). Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget, 7(50), 83208-83222. https://doi.org/10.18632/oncotarget.13079
Tan, Su Fern ; Liu, Xin ; Fox, Todd E. ; Barth, Brian M. ; Sharma, Arati ; Turner, Stephen D. ; Awwad, Andy ; Dewey, Alden ; Doi, Kenichiro ; Spitzer, Barbara ; Shah, Mithun Vinod ; Morad, Samy A.F. ; Desai, Dhimant ; Amin, Shantu ; Zhu, Junjia ; Liao, Jiangang (Jason) ; Yun, Jong ; Kester, Mark ; Claxton, David ; Wang, Hong-Gang ; Cabot, Myles C. ; Schuchman, Edward H. ; Levine, Ross L. ; Feith, David J. ; Loughran, Thomas P. / Acid ceramidase is upregulated in AML and represents a novel therapeutic target. In: Oncotarget. 2016 ; Vol. 7, No. 50. pp. 83208-83222.
@article{74e4bda79653412aada6f3399b5373b9,
title = "Acid ceramidase is upregulated in AML and represents a novel therapeutic target",
abstract = "There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML.",
author = "Tan, {Su Fern} and Xin Liu and Fox, {Todd E.} and Barth, {Brian M.} and Arati Sharma and Turner, {Stephen D.} and Andy Awwad and Alden Dewey and Kenichiro Doi and Barbara Spitzer and Shah, {Mithun Vinod} and Morad, {Samy A.F.} and Dhimant Desai and Shantu Amin and Junjia Zhu and Liao, {Jiangang (Jason)} and Jong Yun and Mark Kester and David Claxton and Hong-Gang Wang and Cabot, {Myles C.} and Schuchman, {Edward H.} and Levine, {Ross L.} and Feith, {David J.} and Loughran, {Thomas P.}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.13079",
language = "English (US)",
volume = "7",
pages = "83208--83222",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

Tan, SF, Liu, X, Fox, TE, Barth, BM, Sharma, A, Turner, SD, Awwad, A, Dewey, A, Doi, K, Spitzer, B, Shah, MV, Morad, SAF, Desai, D, Amin, S, Zhu, J, Liao, JJ, Yun, J, Kester, M, Claxton, D, Wang, H-G, Cabot, MC, Schuchman, EH, Levine, RL, Feith, DJ & Loughran, TP 2016, 'Acid ceramidase is upregulated in AML and represents a novel therapeutic target', Oncotarget, vol. 7, no. 50, pp. 83208-83222. https://doi.org/10.18632/oncotarget.13079

Acid ceramidase is upregulated in AML and represents a novel therapeutic target. / Tan, Su Fern; Liu, Xin; Fox, Todd E.; Barth, Brian M.; Sharma, Arati; Turner, Stephen D.; Awwad, Andy; Dewey, Alden; Doi, Kenichiro; Spitzer, Barbara; Shah, Mithun Vinod; Morad, Samy A.F.; Desai, Dhimant; Amin, Shantu; Zhu, Junjia; Liao, Jiangang (Jason); Yun, Jong; Kester, Mark; Claxton, David; Wang, Hong-Gang; Cabot, Myles C.; Schuchman, Edward H.; Levine, Ross L.; Feith, David J.; Loughran, Thomas P.

In: Oncotarget, Vol. 7, No. 50, 01.01.2016, p. 83208-83222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Acid ceramidase is upregulated in AML and represents a novel therapeutic target

AU - Tan, Su Fern

AU - Liu, Xin

AU - Fox, Todd E.

AU - Barth, Brian M.

AU - Sharma, Arati

AU - Turner, Stephen D.

AU - Awwad, Andy

AU - Dewey, Alden

AU - Doi, Kenichiro

AU - Spitzer, Barbara

AU - Shah, Mithun Vinod

AU - Morad, Samy A.F.

AU - Desai, Dhimant

AU - Amin, Shantu

AU - Zhu, Junjia

AU - Liao, Jiangang (Jason)

AU - Yun, Jong

AU - Kester, Mark

AU - Claxton, David

AU - Wang, Hong-Gang

AU - Cabot, Myles C.

AU - Schuchman, Edward H.

AU - Levine, Ross L.

AU - Feith, David J.

AU - Loughran, Thomas P.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML.

AB - There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML.

UR - http://www.scopus.com/inward/record.url?scp=85004001402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004001402&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13079

DO - 10.18632/oncotarget.13079

M3 - Article

VL - 7

SP - 83208

EP - 83222

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -